Compare Johnson & Johnson (JNJ) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Lucid Group Inc — how do they compare? Johnson & Johnson trades at $260.79 (market cap $618.09B), while Lucid Group Inc trades at $3.78 (market cap $1.51B). The key difference: Johnson & Johnson is far larger — about 409.3× Lucid Group Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Lucid Group Inc for 45 Days on average.
| JNJ | LCID | |
|---|---|---|
Market Cap | $618.09B | $1.51B |
Volume | 6,050,983 | 12,333,745 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $21.92 |
52-Week Low | $186.00 | $3.82 |
Typical Hold Time | 129 Days | 45 Days |
Enterprise Value | $646.37B | $4.40B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Lucid Group (LCID) trades at $3.785, down 2.7% with a bearish technical outlook. The company shows concerning fundamentals with negative profit margins (-249.21% net income margin) and consistent earnings misses. Recent news highlights operational challenges including delayed Cosmos SUV launch and aggressive cost-cutting targets of $1.4 billion for 2026. Cash flow remains negative at -$566 million, though strategic partnerships with Bolt for autonomous vehicles provide some growth potential.
LCID faces significant execution risks amid high cash burn and competitive EV market pressures. Analyst consensus is cautious with 67% hold ratings and $7.60 price target suggesting 101% upside potential. The stock presents high-risk speculation for investors betting on successful turnaround execution and partnership developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
